Detecting and Managing Diabetic Peripheral Neuropathy: What the Evidence Shows
Diabetic peripheral neuropathy (DPN) is one of the most common and consequential complications of diabetes. Estimates of its prevalence vary widely depending on the population and diagnostic criteria, but reviews consistently report that roughly half of people with diabetes will develop nerve damage over the course of their disease, with figures ranging from about 23% to 54% across studies. Because DPN often progresses silently, the loss of protective sensation it causes is a leading factor in the development of foot ulcers, infection, and lower-limb amputation. Understanding how the condition is detected and managed is therefore central to preserving mobility and preventing serious harm.
Why Early Detection Matters
The clinical danger of DPN is not pain but the absence of it. As small and large nerve fibres are damaged, patients gradually lose the ability to perceive pressure, temperature, and minor trauma. A blister, a poorly fitting shoe, or a small puncture can go unnoticed until it has progressed to a deep wound. The International Working Group on the Diabetic Foot (IWGDF), in its 2023 guideline update, recommends that every person with diabetes who is at very low risk be screened at least annually for signs and symptoms of peripheral neuropathy and peripheral artery disease, with more frequent review for those found to be at higher risk. This risk-stratification approach allows clinicians to direct preventive resources toward the patients most likely to ulcerate.
Screening Tools and Their Limits
The cornerstone of bedside screening remains the 10-gram Semmes-Weinstein monofilament, applied to several sites on the sole of the foot to test protective sensation. It is inexpensive, quick, and widely available. However, recent research has highlighted important limitations. A 2024 study published in PLOS One found that the diagnostic accuracy of the 10-gram monofilament can be reduced by factors such as occupation, footwear habits, and the natural thickening of plantar skin, meaning a single negative test does not exclude neuropathy. For this reason, guidelines recommend combining the monofilament with at least one additional test, such as a 128-Hz tuning fork for vibration sense, pinprick testing, or assessment of ankle reflexes. Using more than one modality improves sensitivity and reduces the chance of missing early disease.
Managing the Condition
Management of DPN rests on two distinct goals: slowing the progression of nerve damage and relieving the painful symptoms that some patients experience.
Glycaemic Control and Foot Protection
The single most important disease-modifying intervention is optimised blood glucose control, which has the strongest evidence for slowing nerve damage in type 1 diabetes and a more modest but still meaningful effect in type 2 diabetes. Alongside metabolic management, the IWGDF emphasises structured patient education, daily foot self-inspection, appropriate footwear, and regular professional foot examination. For patients at moderate or high risk, the 2023 guidelines also suggest daily at-home monitoring of foot skin temperature, since a localised rise in temperature can signal inflammation days before a visible ulcer appears.
Treating Painful Neuropathy
A subset of patients experience painful diabetic peripheral neuropathy, characterised by burning, shooting, or electric-shock-like sensations. The 2022 practice guideline from the American Academy of Neurology, published in Neurology, recommends offering pharmacological treatment from four main drug classes shown to reduce pain: gabapentinoids (gabapentin and pregabalin), serotonin-norepinephrine reuptake inhibitors (duloxetine and venlafaxine), tricyclic antidepressants (such as amitriptyline), and certain sodium-channel blockers. The guideline stresses that no single agent is clearly superior for all patients, so therapy should be individualised according to coexisting conditions, side-effect profiles, and patient preference, with the dose titrated and the agent switched if the first choice is ineffective or poorly tolerated. Topical agents and non-pharmacological approaches may serve as useful adjuncts. Importantly, these medications relieve symptoms but do not reverse the underlying nerve damage, reinforcing the central role of prevention and glycaemic control.
Key Takeaways
Diabetic peripheral neuropathy is common, frequently asymptomatic, and a principal driver of diabetic foot complications. Annual screening using more than one simple bedside test improves detection, because tools such as the 10-gram monofilament have real limitations when used alone. Once neuropathy is identified, the priorities are protecting the insensate foot through education and regular examination, optimising blood glucose to slow progression, and, where painful symptoms are present, selecting from established first-line medications tailored to the individual. Together these measures form the evidence-based foundation for reducing the burden of nerve damage and the ulcers and amputations that can follow.
References
Schaper NC, van Netten JJ, Apelqvist J, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024.
Bus SA, Sacco ICN, Monteiro-Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024.
Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. American Academy of Neurology. Neurology. 2022.
Aldhafiri A, et al. The accuracy of 10 g monofilament use for clinical screening of diabetic peripheral neuropathy. PLOS One. 2024.
Conventional management and current guidelines for painful diabetic neuropathy. Diabetes Research and Clinical Practice. 2023.
Comments
